Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Noema Doses First Patients in Phase 2b Trial of Gemlapodect for Tourette Syndrome
Details : NOE-105(gemlapodect) is a potential first-in-class phosphodiesterase-10A (PDE10A) inhibitor in mid-stage clinical development as a dopamine modulator for Tourette syndrome.
Brand Name : NOE-105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2024
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Noema’s NOE-105 Phase 2a Study in Tourette Syndrome Meets All Endpoints
Details : NOE-105 (gemlapodect) is a novel and first-in-class PDE10A inhibitor currently being studied in patients with Tourette syndrome.
Brand Name : NOE-105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 17, 2024
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Noema Pharma Completes Enrollment for Phase 2B GALENE Trial of NOE-101 for Seizures
Details : NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for seizures in Tuberous Sclerosis.
Brand Name : NOE-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 13, 2024
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NOE-115
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Noema Pharma Doses First Patient in Phase 2a Study of NOE-115 for Menopause Symptoms
Details : NOE-115 is a broad-spectrum monoamine modulator, small molecule drug candidate, which is being evaluated for the treatment of women with vasomotor symptoms.
Brand Name : NOE-115
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2024
Lead Product(s) : NOE-115
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Forbion
Deal Size : $112.0 million
Deal Type : Series B Financing
Details : The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and sei...
Brand Name : NOE-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 07, 2023
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Forbion
Deal Size : $112.0 million
Deal Type : Series B Financing
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Noema Pharma Receives FDA Fast Track Designation for Basimglurant (NOE-101) in Trigeminal Neuralgia
Details : Basimglurant (NOE-101) is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) for the treatment of trigeminal neuralgia (TN).
Brand Name : NOE-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 18, 2022
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NOE-101 (basimglurant), a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN.
Brand Name : NOE-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2022
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NOE-105 (gemlapodect) is an inhibitor of PDE10A, an enzyme highly expressed in medium spiny neurons of mammalian striatum, which modulates dopamine D2 receptor signaling and does not appear to be associated with metabolic abnormalities that are typically...
Brand Name : NOE-105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2022
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NOE-105 (gemlapodect) is an inhibitor of PDE10A, an enzyme highly expressed in medium spiny neurons of the mammalian striatum, which modulates D2 receptor signaling that are typically observed with most second-generation antipsychotics.
Brand Name : NOE-105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2022
Lead Product(s) : Gemlapodect
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Sofinnova Partners
Deal Size : $59.0 million
Deal Type : Series A Financing
Details : Financing will advance the development of four clinical-stage product candidates including lead product NOE-101. The product candidates will be developed in neurological indications with severe unmet need.
Brand Name : NOE-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 01, 2020
Lead Product(s) : Basimglurant
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Sofinnova Partners
Deal Size : $59.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?